A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).

被引：14
|
作者：
Bekaii-Saab, Tanios S.
Starodub, Alexander
El-Rayes, Bassel F.
O'Neil, Bert H.
Shanda, Safi
Ciombor, Kristen Keon
Noonan, Anne M.
Hanna, Wahid Tewfik
Sehdev, Amikar
Shaib, Walid Labib
Mikhail, Sameh
Neki, Anterpreet S.
Oh, Cindy
Li, Youzhi
Li, Wei
Borodyansky, Laura
Li, Chiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4106
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer
    Dotan, Efrat
    Cardin, Dana B.
    Lenz, Heinz-Josef
    Messersmith, Wells
    O'Neil, Bert
    Cohen, Steven J.
    Denlinger, Crystal S.
    Shahda, Safi
    Astsaturov, Igor
    Kapoun, Ann M.
    Brachmann, Rainer K.
    Uttamsingh, Shailaja
    Stagg, Robert J.
    Weekes, Colin
    CLINICAL CANCER RESEARCH, 2020, 26 (20) : 5348 - 5357
  • [42] A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
    Jameson, Gayle S.
    Borazanci, Erkut Hasan
    Babiker, Hani M.
    Poplin, Elizabeth
    Niewiarowska, Anna A.
    Gordon, Michael S.
    Barrett, Michael T.
    Ansaldo, Karen
    Lebron, Leticia
    Stoll, Amy C.
    Rosenthal, Adam
    Shemanski, Lynn R.
    Korn, Ronald Lee
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
    Firdaus, Irfan
    Waterhouse, David Michael
    Gutierrez, Martin
    Wainberg, Zev A.
    George, Ben
    Kelly, Karen
    Bekaii-Saab, Tanios S.
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Fraser, Cindy Duval
    Ko, Amy
    Pierce, Daniel W.
    Manax, Victoria G.
    Stergiopoulos, Sotirios G.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [44] Phase II study of nab-paclitaxel/gemcitabine (NabP-Gem) alternating with FOLFIRI as 1st line therapy (Rx) in patients (pts) with metastatic pancreatic cancer (mPC).
    Picozzi, Vincent J.
    Leach, Joseph
    Larson, Tim
    Nishikubo, Carol Y.
    Anthony, Stephen Patrick
    Lin, Bruce S.
    Bolejack, Vanessa
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer
    Ramanathan, Ramesh K.
    Lee, Peter
    Seng, John E.
    Anthony, Stephen Patrick
    Rosen, Peter J.
    Mena, Raul R.
    Picozzi, Vincent J.
    Sachdev, Jasgit C.
    Larson, Tim
    Korn, Ronald
    Jameson, Gayle S.
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Leach, Joseph W.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [46] Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer
    Ramanathan, Ramesh K.
    Lee, Peter
    Leach, Joseph W.
    Anthony, Stephen Patrick
    Weiss, Glen J.
    Rosen, Peter J.
    Picozzi, Vincent J.
    Sachdev, Jasgit C.
    Larson, Tim
    Korn, Ronald
    Hu, Chengcheng
    Jameson, Gayle S.
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Seng, John E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [47] A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) plus /- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer
    Hidalgo, Manuel
    Cooray, Prasad
    Jameson, Michael B.
    Carrato, Alfredo
    Parnis, Francis
    Jeffery, Mark
    Grimison, Peter S.
    Stagg, Robert J.
    Kapoun, Ann M.
    Dupont, Jakob
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, W.
    Kornek, G.
    Prager, G.
    Stranzl, N.
    Laengle, F.
    Schindl, M.
    Friedl, J.
    Klech, J.
    Roethlin, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [49] Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, Werner
    Kornek, Gabriela
    Prager, Gerald
    Stranzl, Nadja
    Laengle, Friedrich
    Schindl, Martin
    Friedl, Josef
    Klech, Julia
    Roethlin, Sabine
    Zielinski, Christoph
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (02) : 234 - 238
  • [50] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
    Tempero, M.
    Oh, D-Y
    Tabernero, J.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D-T
    Starling, N.
    Bachet, J-B
    Chang, H-M
    Maurel, J.
    Garcia-Carbonero, R.
    Lonardi, S.
    Coussens, L. M.
    Fong, L.
    Tsao, L. C.
    Cole, G., Jr.
    James, D.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 600 - 608
12345